News Archive

Highlighted Articles
- September 24, 2024
  Since arriving at the University in 2010, the president has contributed to and overseen a rich variety of advancements that transformed the University’s campus, culture and community.
- April 30, 2024
  Steven E. Kern, PhD, Executive Director, Global Health (GH) Labs, will present the Dr. Jeffrey S. Barrett '86 Endowed Annual Lecture on Monday, May 6, 2024 as part of a joint seminar hosted by the Coulter-Drexel Translational Research Program and 91��Ƭ��'s School of Biomedical Engineering, Science and Health Systems. The title of the seminar is "Catalyzing Innovation To Improve Healthcare in Low Resource Settings."
Highlighted Articles
- September 29, 2023
  The Coulter-Drexel Translational Research Program was honored to host researchers from the Mansfield Foundation's Mansfield-PhRMA Research Scholars Program, which is a U.S.–Japan exchange that brings young researchers from Japan’s pharmaceutical and development field to the United States each year to learn about U.S. healthcare policy, pharmaceutical research, regulatory practices, and translational research.
- March 14, 2023
  
  Drexel Materials PhD student Emily Herbert (BS ’19, advisor: Caroline Schauer) has received a 2023 U.S. Fulbright Student Award for her proposed project, “Scaling Up Production of Polyhydroxyalkanoates (PHAs).”
- March 7, 2023
  
  Kara Spiller, PhD, professor in the School of Biomedical Engineering, Science and Health Systems, has designed a new interdisciplinary course to introduce first-year students to cell and gene therapy, the science behind it and other aspects of this emerging area of the life sciences industry that is playing an increasing role at Drexel.
- January 5, 2023
  91��Ƭ�� has launched the Innovation Fund, which invests in early-stage Drexel student and postgraduate startups, as well as startups founded to commercialize the results of Drexel scientific research.
Highlighted Articles
- November 21, 2022
  A team of researchers from 91��Ƭ�� has proposed a way to detect Lyme disease by looking for a unique polymer-protein indicator that occurs before the immune reaction is triggered. The group’s method recently received a boost from a U.S. Department of Health and Human Services and the Steve & Alexandra Cohen Foundation initiative to finally find an effective test for the disease.
- November 21, 2022
  
  Nearly half a million people become infected with Lyme disease in the United States each year — a number expected to grow as climate change expands the range of the ticks that carry it. But despite its status as the country’s most common vector-borne disease, there is still no reliable way to detect the infection in its early stages — when treatment is most effective
- July 12, 2022
  
  It can take inventors years to receive an official U.S. patent, usually represented by a seven-digit number. But the full story behind most patents is much longer. When a professor found that he was lacking a key tool in his field, he and his colleagues set out to build an alternative that was even better. Their patent was approved in 2021, and this is the story of how it came to be.
- June 8, 2022
  Two 91��Ƭ�� doctoral students are studying ways to improve a revolutionary ankle replacement implant patented by their professor.
- February 3, 2022
Highlighted Articles
- December 17, 2021
- November 30, 2021
  Mihir Shah, cofounder of the University City company, made his first-ever in-person pitch to investors including Apple cofounder Steve Wozniak and former *NSYNC member Lance Bass.
- May 26, 2021
  
  A drug development company attempting to commercialize a high-tech imaging agent developed by researchers and physicians at 91��Ƭ�� has raised $4 million.
- May 14, 2021
  
  Kinos was founded in 2017 to translate and commercialize Coulter Foundation funded biomechanics research, led by professor Sorin Siegler, Ph.D. Together as an interdisciplinary team of clinical thought leaders, engineers, scientists, and investors, "Kinos is focused on improving the surgical options available to preserve motion in patients with ankle arthritis. The Axiom total ankle is the first biomechanically accurate implant on the market, offering motion in all three anatomic planes, as is seen in the natural ankle," said Brian Garvey, CEO of Kinos Medical. "We are thrilled to partner with the restor3d team to combine our advanced technologies into a holistic product offering."
- April 29, 2021
  <p style="margin: 0in;">91��Ƭ��’s MXene material is one step closer to transforming the lives of people suffering from end-stage kidney disease. Nephria Bio, Inc., a U.S.-based spin-off of the South Korean medical device company EOFlow Co., Ltd., has signed a licensing agreement with the University to use the two-dimensional material, discovered at Drexel, as a filter in a wearable artificial kidney device it is developing. The technology could allow many of the millions of people suffering from end-stage kidney disease worldwide to move more freely, without spending hours each week anchored to large dialysis machines.</p>
  <p style="margin: 0in;"> </p>
Highlighted Articles
- August 25, 2020
  
  Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announces the signing of an exclusive, worldwide license agreement of a 91��Ƭ�� research program to Rain for small molecule inhibitors of RAD52, a critical molecule involved in the DNA damage response (DDR) pathway. The agreement expands Rain’s targeted oncology pipeline to include synthetic lethal strategies for the treatment of cancers associated with mutations in the DDR pathway, including breast and ovarian cancers characterized by BRCA1/2 mutations.
- August 1, 2020
  
  Alex Mazin wins DOD and NIH grants totaling $2.844 Million to support his development of Inhibitors of RAD52 as a Therapy Against BRCA-Deficient cancers.
- June 30, 2020
  
  Congratulations to Kinos Medical who received their 501(k) Substantially equivalent determination for their Axiom Total Ankle Sytem from the FDA.
- June 26, 2020
  A new report from the George W. Bush Institute and the innovation consulting firm Opus Faveo Innovation Development named Drexel the most innovative mid-sized research university in the country.
- June 25, 2020
Highlighted Articles
- August 20, 2019
- August 20, 2019
  
  Ticks carry a multitude of bacteria that can harm human health, and a College of Medicine doctoral student is identifying all of them, in hopes of giving physicians ammunition against Lyme disease...
- July 24, 2019
- June 5, 2019
  The University moved up three spots among the colleges and universities in a rankings report authored by the National Academy of Inventors and the Intellectual Property Owners Association.
Highlighted Articles
- July 10, 2018
  The University’s Coulter-Drexel Translational Research Partnership Program recently met the metrics to continue its innovative programming for another three years.
- June 6, 2018
  The University was included among the colleges and universities in the Top 100 Worldwide Universities Granted U.S. Utility Patents report authored by the National Academy of Inventors (NAI) and the Intellectual Property Owners Association (POA).
- May 23, 2018
  
  Maëlys enrolled in the joint MD/MBA program offered through a partnership between LeBow and the 91��Ƭ��. It involves completing an abbreviated MBA between the third and fourth years of medical school, with academic credit for business courses offered through DUCOM making up the balance. A select few medical students take part each year, and she was determined to get the most of the experience. That drive led her to completing a fellowship through the Coulter-Drexel Translational Research Partnership Program...
- January 23, 2018
  
  In the course of her career as a fund manager, she has reviewed around 150 startups and funded about 30. Hear how the program and fund she manages work at Drexel, and how she reviews and evaluates applicants.
Highlighted Articles
- October 17, 2017
  
  Context Therapeutics presented at the annual BIO Investor Forum on October 17-18, 2017. This event brings together blue chip institutional investors and emerging companies. 150 companies are selected to present, almost all of which are late stage private or public companies. 10 slots are reserved for company’s that have raised < $25M of capital and Context was selected as one of those 10 companies.
- August 17, 2017
  
  Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis, and neurodegenerative disease, today announced that the company has entered into agreements with three research partners.
- August 4, 2017
- July 6, 2017
  
  The Coulter-Drexel Translational Research Partnership is pleased to announce the following six projects have been awarded funding for 2017-18. The mission of the Coulter-Drexel Translational Research Partnership is to partner with 91��Ƭ�� faculty to develop products that will save, extend, and improve the lives of patients suffering from any disease or condition. Since inception of the program in 2005 nearly 50 projects have received a total of $7.6 million in support.
- May 18, 2017
  A team of Sidney Kimmel Cancer Center (SKCC) investigators from Thomas Jefferson University and 91��Ƭ�� have recently published a new study in the journal Cancer Research that sheds light on a key mechanism of prostate cancer progression.
Highlighted Articles
- December 16, 2016
  
  For 18-year-old Farheen Jahan, life took an ugly turn when she discovered a stiff growth in her breast. However, initial blood reports failed to detect anything serious. Later, in a health camp clinic set up in her locality in rural India she got herself scanned again with something called iBreastExam – a diagnostic tool designed to perform painless and radiation free breast scans, providing results instantly at the point of care. The scan detected abnormal tissue in her breast.
- November 29, 2016
  Drexel researchers have received a $3 million NIH grant to test a new treatment for the millions of patients who suffer from slow-healing, chronic wounds.
- September 20, 2016
  
  PolyCore Therapeutics LLC, has been selected as one of the companies presenting at the University Startups Demo Day on September 20 in Washington, DC.
- June 24, 2016
  During the first year of Drexel’s Coulter Fellows Program in the School of Biomedical Engineering, Science and Health Systems, graduate students across the University worked together on medical and engineering research.
- June 23, 2016
  
  When PolyCore Therapeutics, a Drexel spinout, began developing a breakthrough drug to manage the symptoms of Parkinson’s Disease, CEO Jim Harris and Sandhya Kortagere (pictured) quickly realized that they could hasten their journey to funding via the Science Center’s newest commercialization program, Phase 1 Ventures.
Highlighted Articles
- January 23, 2015
  How the Coulter Program is helping to bring a breakthrough Parkinson’s treatment — and other Drexel discoveries — out of the academy and into the marketplace.
- January 19, 2015
  
  Jim currently serves as the CEO of PolyCore Therapeutics, a spin-out from 91��Ƭ��, focused on the development of a treatment for Parkinson’s Disease. Jim is also the CEO of LignaMed, LLC a spin-out from the University of Pennsylvania, focused on the development of an agent to improve outcomes in the treatment of chest Mr. Harris is the Co-founder and COO of FHK LLC, a company focused on acquisition and commercialization of specialty pharmaceutical products.
Highlighted Articles
- August 4, 2014
  Wound healing technology developed at 91��Ƭ�� is one step closer to becoming a tool for medical caregivers. Eqalix, Inc., a Northern Virginia regenerative medicine device company, recently received patent protection for a protein-based nanofiber scaffold technology invented by Drexel researchers.
- May 19, 2014
  Tummy snugging maternity wear could soon be giving expecting parents peace of mind in addition to stylishly securing waistlines. Researchers at 91��Ƭ�� are combining fashion design with wireless technology to produce a belly band that will be able to monitor uterine contractions and fetal heart rate in real time.
Highlighted Articles
- December 10, 2013
  For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.
- November 25, 2013
  Medical-device inventor Wallace Coulter never married, and he had no children. But he does have heirs, and Drexel is one of them.
Highlighted Articles
- October 10, 2012
  A wristwatch that can check your blood pressure, a belly band for expecting mothers to monitor their baby’s vital signs and a way for doctors to sterilize their hands without getting them wet – these innovations are just a few of the ideas that will be on display as 91��Ƭ�� and the Wallace H. Coulter Foundation provide a glimpse into the future of medical technology at the Innovation Technology & Talent Showcase on Oct. 31.
- August 20, 2012
  Physicians could soon have a new, noninvasive and radiation-free option when it comes to performing regular breast exams. A hand-held device, using technology developed at 91��Ƭ��, that can detect cancer by sensing the elasticity of breast tissue is moving into the final stages of testing and development with help from a Pennsylvania Department of Health grant.
Highlighted Articles
- April 26, 2011
  91��Ƭ�� was awarded $10 million by the Wallace H. Coulter Foundation to endow the Coulter Translational Research Partnership program. The University matched the Coulter Foundation’s $10 million grant creating a $20 million endowment to bring life saving solutions to clinical practice by moving promising biomedical discoveries to commercialization.

91��Ƭ��

News Archive